Merck's Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission's Approval as a 1L Therapy for Advanced Renal Cell Carcinoma
Shots:
- The approval is based on P-III KEYNOTE-426 study assessing Keytruda (200mg) + Inlyta (5mg) vs Sunitinib (50mg) in 861 patients in a ratio (1:1) with advanced RCC regardless of PD-L1 tumor expression and IMDC risk group
- The P-III KEYNOTE-426 study results: improvement in OS- 47% reduction in risk of death- m-PFS (15.1 vs 11.0 mos.); ORR (59% vs 36%); CRR (6% vs 2%); PRR (53% vs 34%). The approval allows marketing of Keytruda dual regimen in all 28 EU member states + Iceland- Lichtenstein and Norway
- KEYTRUDA is an anti-PD-1 therapy- act blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells and is the first anti-PD-1 therapy to be approved in EU as combination therapy for RCC across all IMDC risk groups
Click here to read full press release/ article
Ref: Business Wire | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com